Efficacy and Safety of Glecaprevir/Pibrentasvir Combination Therapy in Genotype 1b Chronic Hepatitis C Patients with and without Cirrhosis Undergoing Hemodialysis

DOI Web Site Web Site 1 References Open Access
  • Atsukawa Masanori
    Division of Gastroenterology and Hepatology, Nippon Medical School
  • Kondo Chisa
    Division of Gastroenterology and Hepatology, Nippon Medical School
  • Nakamuta Makoto
    Department of Gastroenterology, National Hospital Organization Kyushu Medical Center
  • Toyoda Hidenori
    Department of Gastroenterology, Ogaki Municipal Hospital
  • Kumada Takashi
    Department of Gastroenterology, Ogaki Municipal Hospital
  • Takaguchi Koichi
    Department of Hepatology, Kagawa Prefectural Central Hospital
  • Watanabe Tsunamasa
    Department of Internal Medicine, St. Marianna University School of Medicine
  • Ikeda Hiroki
    Department of Internal Medicine, St. Marianna University School of Medicine
  • Michitaka Kojiro
    Gastroenterology Center, Ehime Prefectural Central Hospital
  • Hiraoka Atsushi
    Gastroenterology Center, Ehime Prefectural Central Hospital
  • Asai Akira
    Second Department of Internal Medicine, Osaka Medical College
  • Fukunishi Shinya
    Second Department of Internal Medicine, Osaka Medical College
  • Shimada Noritomo
    Division of Gastroenterology and Hepatology, Otakanomori Hospital
  • Mikami Shigeru
    Division of Gastroenterology, Department of Internal Medicine, Kikkoman General Hospital
  • Uojima Haruki
    Department of Gastroenterology, Kitasato University School of Medicine
  • Genda Takuya
    Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital
  • Abe Hiroshi
    Division of Gastroenterology and Hepatology, Shinmatusdo Central General Hospital
  • Kato Keizo
    Division of Gastroenterology and Hepatology, Shinmatusdo Central General Hospital
  • Ogawa Chikara
    Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital
  • Ikegami Tadashi
    Division of Hepatology and Gastroenterology, Tokyo Medical University, Ibaraki Medical Center
  • Tsubota Akihito
    Core Research Facilities for Basic Science, The Jikei University School of Medicine
  • Asano Toru
    Division of Gastroenterology and Hepatology, Tokyo Metropolitan Bokutoh Hospital
  • Nozaki Akito
    Gastroenterological Center, Yokohama City University Medical Center
  • Arai Taeang
    Nippon Medical School Chiba Hokusoh Hospital
  • Itokawa Norio
    Nippon Medical School Chiba Hokusoh Hospital
  • Iio Etsuko
    Department of Virology and Liver Unit, Graduate School of Medical Sciences, Nagoya City University
  • Tanaka Yasuhito
    Department of Virology and Liver Unit, Graduate School of Medical Sciences, Nagoya City University
  • Iwakiri Katsuhiko
    Division of Gastroenterology and Hepatology, Nippon Medical School

Bibliographic Information

Other Title
  • 血液透析施行中のゲノタイプ1のC型慢性肝炎・代償性肝硬変患者に対するグレカプレビル・ピブレンタスビル併用療法の有効性と安全性：KTK49 Liver Study Group
  • ケツエキ トウセキ シコウ チュウ ノ ゲノタイプ 1 ノ Cガタ マンセイ カンエン ・ ダイショウセイ カンコウヘン カンジャ ニ タイスル グレカプレビル ・ ピブレンタスビル ヘイヨウ リョウホウ ノ ユウコウセイ ト アンゼンセイ : KTK49 Liver Study Group

Search this article

Description

<p>In this prospective multicenter study, we evaluate the efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) combination therapy for genotype 1b chronic hepatitis C patients undergoing hemodialysis. Of 17 patients who received GLE/PIB for 8 or 12 weeks, 11 completed the treatment and the 12-week follow-up care that followed. All 11 patients (100%) achieved sustained virologic response 12 (SVR12). Adverse events were observed in 41.2% of all patients and the most frequent adverse event was pruritus. This study suggests that GLE/PIB combination therapy is highly effective and safe even in genotype 1b chronic hepatitis C patients undergoing hemodialysis.</p>

Journal

  • Kanzo

    Kanzo 59 (10), 578-580, 2018-10-20

    The Japan Society of Hepatology

References(1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top